Results 211 to 220 of about 47,030 (243)

Thalidomide

Reactions Weekly, 2008
  +4 more sources

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

Nature Reviews Clinical Oncology, 2021
Max Jan, Adam S Sperling, Benjamin L Ebert   +2 more
exaly  

Thalidomide Polyneuropathy

New England Journal of Medicine, 1962
openaire   +2 more sources

Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

Ca-A Cancer Journal for Clinicians, 2013
Susanna B Park, David Goldstein, Martin Koltzenburg   +2 more
exaly  

Thalidomide: Reversible Dementia

Clin-Alert, 2003
openaire   +1 more source

Thalidomide

Reactions Weekly, 2010
openaire   +2 more sources

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Lancet, The, 2019
Phillipe Moreau, Michel M Attal, `Cyrille Hulin   +2 more
exaly  

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Lancet, The, 2007
Thierry Facon, Michel M Attal, Ibrahim Yakoub Agha   +2 more
exaly  

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

Lancet, The, 2006
Antonio Palumbo, Sara Bringhen, Valerio De Stefano   +2 more
exaly  

Thalidomide

Cancer Practice, 2000
openaire   +2 more sources